<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817060</url>
  </required_header>
  <id_info>
    <org_study_id>SRB_201807_150</org_study_id>
    <nct_id>NCT03817060</nct_id>
  </id_info>
  <brief_title>CuMulativE Live bIrth Rate of Patients at High Risk of OHSS After Freeze-all Embryos at Cleavage or blAstocyst Stage</brief_title>
  <acronym>MELISSA</acronym>
  <official_title>CuMulativE Live bIrth Rate of Patients at High Risk of OHSS After Freeze-all Embryos at Cleavage or blAstocyst Stage in a Single Embryo Transfer Setting (MELISSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Libre de Bruxelles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Libre de Bruxelles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian stimulation for the induction of multifollicular growth by gonadotrophins represents&#xD;
      an important part of In Vitro Fertilization (IVF). However, the use of these drugs can be&#xD;
      associated with side effects, from which the most common is the Ovarian Hyperstimulation&#xD;
      Syndrome (OHSS). Stimulation with gonadotrophins in a Gonadotropin-releasing hormone (GnRH)&#xD;
      antagonist cycle rather than a GnRH agonist cycle reduces significantly the risk of OHSS.&#xD;
      During stimulation, the best predictor of severe OHSS is the number of follicles &gt;10mm on the&#xD;
      day of triggering final oocyte maturation, with the threshold at ≥16 follicles. When this&#xD;
      occurs, final oocyte maturation can be induced with a GnRH agonist, reducing further the risk&#xD;
      the syndrome. To perform a fresh embryo transfer, 1500 IU human Chorionic Gonadotropin (hCG)&#xD;
      can be administered on the day of oocyte retrieval for the luteal support. However, with this&#xD;
      procedure there are still some cases of OHSS. To overcome this, it is suggested to combine&#xD;
      GnRH agonist triggering with a freeze-all embryos strategy and perform embryo replacement in&#xD;
      subsequent frozen-thawed embryo transfer (FET) cycles. Different cryopreservation strategies&#xD;
      are been performed according to the procedure of each fertility center, such as&#xD;
      cryopreservation at 2 pronuclear (2PN), cleavage or blastocyst stage. The aim of this study&#xD;
      is to determine the optimal strategy for the freeze-all cycles and particularly the optimal&#xD;
      day for freezing, thawing and transferring the embryos. The hypothesis is that there will&#xD;
      increased cumulative live birth rates per started cycle in blastocyst compared to cleavage&#xD;
      stage FET cycles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative live birth</measure>
    <time_frame>within one year of randomisation</time_frame>
    <description>Cumulative live birth rate per oocyte retrieval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frozen thawed embryo transfer cycles needed to achieve live birth</measure>
    <time_frame>within one year of randomisation</time_frame>
    <description>Number of frozen thawed embryo transfer cycles needed to achieve live birth</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Cleavage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Embryos cryopreserved with vitrification at the cleavage stage (day 3) of embryo development</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blastocyst</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Embryos cryopreserved with vitrification at the blastocyst stage (day 5 or 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cryopreservation of embryos at cleavage stage</intervention_name>
    <description>cryopreservation of embryos at cleavage stage (day 3) of embryo development</description>
    <arm_group_label>Cleavage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cryopreservation of embryos at blastocyst stage</intervention_name>
    <description>cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development</description>
    <arm_group_label>Blastocyst</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &lt;40 years old&#xD;
&#xD;
          -  Indication for In Vitro Fertilisation (IVF)/Intracytoplasmic sperm injection (ICSI)&#xD;
&#xD;
          -  No more than 2 previous failed IVF/ICSI cycles&#xD;
&#xD;
          -  Stimulation in GnRH antagonist cycle&#xD;
&#xD;
          -  Presence of ≥16 follicles of &gt;10mm on the day of triggering of final oocyte maturation&#xD;
&#xD;
          -  GnRH agonist trigger (triptorelin 0.2mg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cycles with testicular sperm extraction&#xD;
&#xD;
          -  Preimplantation genetic diagnosis&#xD;
&#xD;
          -  Patients with uterine malformations&#xD;
&#xD;
          -  Patients with infectious diseases&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Theoni Tarlatzi</last_name>
    <phone>+3225558948</phone>
    <email>nonika.tarlatzi@gmail.com</email>
  </overall_contact>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Libre de Bruxelles</investigator_affiliation>
    <investigator_full_name>Theoni Tarlatzi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>OHSS</keyword>
  <keyword>Agonist trigger</keyword>
  <keyword>freeze-all</keyword>
  <keyword>blastocyst</keyword>
  <keyword>cleavage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

